Unicycive Therapeutics' OLC shows promise in treating hyperphosphatemia by reducing pill burden and adverse events, potentially gaining FDA approval by June 2025.
ORIC Pharmaceuticals presented new data on two cancer drug candidates, ORIC-944 and ORIC-613, at the AACR Annual Meeting, showing potential in overcoming therapeutic resistance in cancer. ORIC-944 targets prostate cancer with a promising clinical half-life, while ORIC-613 shows synthetic lethality in TRIM37-high tumor models.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.